China

Chinese flag
#Cell line development #China #Sphere Bio

Sphere Bio expands operations in China

Sphere Bio has appointed Redbert Biotechnology (张伟) as its exclusive distribution partner in China.   The deal forms a part of the company’s broader operational scale-up in the APAC region and solidifies its presence in one of the world’s largest and fastest-growing life sciences markets. … Read More

#News

Chinese flag
#Ascentage Pharma #Blood cancer #China #Haematology #Oncology

Ascentage celebrates inclusion in Chinese oncology guidelines

Two of Ascentage Pharma’s drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines.   Lisaftoclax (APG-2575), an investigational novel oral Bcl-2 selective inhibitor, received its first recommendation in the CSCO Guidelines for the Diagnosis and Treatment of Lymphoid Malignancies.  This makes… Read More

#News

#Biotech #Business #China #Drug discovery #Funding

How has the biotech international market planning evolved

Sam Tomlinson, Vice President of Global Drug Safety at Arriello unpacks North America/EU research which compares today’s commercialisation strategies with those of five years ago.   As biotechs around the world look to new territories including emerging markets for their next returns, many are encountering unexpected hurdles. Too often, there is a… Read More

#Exclusive Content

Beijing city centre
#AstraZeneca #China #Investment

AZ invests $2.5bn in R&D centre and collaborations in Beijing 

AstraZeneca has announced an investment of $2.5 billion in Beijing to establish its sixth global strategic R&D centre, together with further research and manufacturing agreements in China.   This investment over the next five years is part of a strategic partnership with the Beijing Municipal Government and the Beijing Economic-Technological Development… Read More

#Business & Investment #News

CAR-T therapy
#CAR-T #Cell therapy #China #Legend Biotech #Myeloma #Oncology

Legend Biotech secures China cilta-cel approval for multiple myeloma

Legend Biotech (a subsidiary of GenScript Biotech) has received approval from the China National Medical Products Administration (NMPA) for cell therapy product, ciltacabtagene autoleucel (cilta-cel). The treatment is approved for use in adults with relapsed or refractory multiple myeloma (MM) who have undergone at least three prior lines of therapy,… Read More

#News #Regulatory

Woman using an asthma inhaler
#Asthma #CAR-T #Cell therapy #China #Preclinical investigations

Researchers push asthma into remission with one dose of CAR-T

A single dose of long-lived chimeric antigen receptor (CAR)-T therapy led to sustained repression of lung inflammation and alleviation of asthmatic symptoms in a new study. The paper, ‘A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice’, was… Read More

#Editor's Choice #News

Stem cell transplant
#China #Cytomegalovirus #Phase III trial #Stem cell transplant #Takeda #Transplant

China’s NMPA okays maribavir for post-transplant cytomegalovirus

Takeda’s Livtencity (maribavir) has been approved in China for the treatment of adult patients with post-hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) cytomegalovirus (CMV) infection/disease. It has been licensed by the National Medical Products Administration (NMPA) in cases where the infection is resistant to treatment with ganciclovir,… Read More

#News #Regulatory

Non-small cell lung cancer
#Apollomics #Avistone Biotechnology #China #Non-small cell lung cancer (NSCLC) #Oncology

c-Met inhibitor approved in China for lung cancer

The Chinese National Medical Products Administration (NMPA) has granted conditional approval to Apollomics’ partner Avistone Biotechnology to commercialise vebreltinib (APL-101) in China for MET exon 14 skipping non-small cell lung cancer (NSCLC). "The NMPA approval of vebreltinib is an important milestone toward providing a new treatment option for patients with… Read More

#News #Regulatory

Chinese flag
#China #HIV #Regulatory #ViiV Healthcare

Chinese regulator approves complete HIV-1 injectable

The National Medical Products Administration (NMPA) of China has approved ViiV Healthcare’s Vocabria (cabotegravir injection) in combination with Janssen's Rekambys (rilpivirine long-acting injection) for the treatment of HIV-1 infection. Cabotegravir injection and tablets were approved in China in July 2023. Cabotegravir injection is indicated in adults who are virologically suppressed,… Read More

#News #Regulatory

CAR-T therapy
#Cancer research #CAR-T #CARsgen Therapeutics #China #Oncology #Solid tumours

CAR T therapy successfully treats solid tumours in China

CARsgen has published evidence of over seven years of disease-free survival in advanced hepatocellular carcinoma (HCC) following treatment with its CAR-GPC3 T cell therapy. Hepatocellular carcinoma is one of the most common malignant tumours, with approximately 780,000 annual incidence cases globally. Recurrence and metastasis are common. Read More

#Cancer Research #Editor's Choice #News

Heart monitor
#AstraZeneca #China #Heart failure #Phase III trial #Regulatory

Forxiga use extended to more heart failure patients in China

AstraZeneca’s Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalisation for heart failure (HF), or urgent HF visits in adults with symptomatic chronic HF. The drug was previously approved in China but was limited to HF patients with reduced ejection fraction (HFrEF). The approval… Read More

#News #Regulatory

Vaccine vial and syringe
#Cancer research #Cancer vaccine #China #Oncology #Solid tumours #Vaccines

Chinese regulator approves personalised cancer vaccine trial

Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours. This breakthrough marks the first of its kind in China and represents a significant milestone… Read More

#Cancer Research #News

Urinary system
#Cancer treatment #China #Oncology #Phase II trial #Regulatory

Astellas’ urothelial cancer drug approved in China

China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for enfortumab vedotin for urothelial cancer. The approval is in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy. “In China, there were nearly 86,000… Read More

#News #Regulatory

Chronic gout
#Atom Bioscience #China #Clinical trial #Gout #hyperuricemia #Phase II trial

URAT1 inhibitor controls chronic gout at low doses

Atom Bioscience has revealed positive results from its China Phase IIa clinical trial of ABP-671, its URAT1 inhibitor for chronic gout.  The randomised, double-blind, placebo-controlled trial enrolled 54 patients with gout or  across six cohorts, with seven randomised to ABP-671 and two to placebo per cohort. … Read More

#News

CAR-T therapy
#Cancer research #CAR-T #CARsgen Therapeutics #China #Collaboration #Huadong Medicine #Immunotherapy #Myeloma #Oncology #Partnership

Partners to commercialise CAR-T product in China

CARsgen Therapeutics and Huadong Medicine (Hangzhou) will collaborate on the commercialisation of CARsgen's BCMA CAR-T product CT053 in mainland China.  CT053 (zevorcabtagene autoleucel, Zevor-cel) is CARsgen's lead drug candidate and an autologous CAR T cell product treating relapsed/refractory multiple myeloma (R/R MM).  Dr Zonghai Li, Chairman of the Board, Chief… Read More

#Business & Investment #News